Evidence map›Paper›PMID 33651802›Full record

ArticlePloS one2021

Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies.

Fouad Chouairi, Clancy W Mullan, Sounok Sen, Makoto Mori, Michael Fuery, Robert W Elder, Joshua Lesse, Kelsey Norton, Katherine A Clark, P Elliott Miller and 9 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Fouad ChouairiYale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0001-8715-6718
Clancy W MullanYale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-2774-251X
Sounok SenYale School of Medicine, New Haven, Connecticut, United States of America.
Makoto MoriYale School of Medicine, New Haven, Connecticut, United States of America.
Michael FueryYale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0001-9166-4838
Robert W ElderSection of Pediatric Cardiology, Yale School of Medicine, New Haven, Connecticut, United States of America.
Joshua LesseSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Kelsey NortonSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Katherine A ClarkYale School of Medicine, New Haven, Connecticut, United States of America.
P Elliott MillerYale School of Medicine, New Haven, Connecticut, United States of America.
David MulliganYale School of Medicine, New Haven, Connecticut, United States of America.
Richard FormicaYale School of Medicine, New Haven, Connecticut, United States of America.
Joseph G RogersDivision of Cardiology, Duke University Medical Center, Durham, North Carolina, United States of America.
Daniel JacobyYale School of Medicine, New Haven, Connecticut, United States of America.
Christopher MaulionYale School of Medicine, New Haven, Connecticut, United States of America.
Muhammad AnwerYale School of Medicine, New Haven, Connecticut, United States of America.
Arnar GeirssonYale School of Medicine, New Haven, Connecticut, United States of America.
Nihar R DesaiYale School of Medicine, New Haven, Connecticut, United States of America.
Tariq AhmadYale School of Medicine, New Haven, Connecticut, United States of America.
Yale University · USDuke Medical Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundPatients with restrictive or hypertrophic cardiomyopathy (RCM/HCM) and congenital heart disease (CHD) do not derive clinical benefit from inotropes and mechanical circulatory support. Concerns were expressed that the new heart allocation system implemented in October 2018 would disadvantage these patients. This paper aimed to examine the impact of the new adult heart allocation system on transplantation and outcomes among patients with RCM/HCM/CHD.

methodsWe identified adult patients with RCM/HCM/CHD in the United Network for Organ Sharing (UNOS) database who were listed for or received a cardiac transplant from April 2017-June 2020. The cohort was separated into those listed before and after allocation system changes. Demographics and recipient characteristics, donor characteristics, waitlist survival, and post-transplantation outcomes were analyzed.

resultsThe number of patients listed for RCM/HCM/CHD increased after the allocation system change from 429 to 517. Prior to the change, the majority RCM/HCM/CHD patients were Status 1A at time of transplantation; afterwards, most were Status 2. Wait times decreased significantly for all: RCM (41 days vs 27 days; P<0.05), HCM (55 days vs 38 days; P<0.05), CHD (81 days vs 49 days; P<0.05). Distance traveled increased for all: RCM (76 mi. vs 261 mi, P<0.001), HCM (88 mi. vs 231 mi. P<0.001), CHD (114 mi vs 199 mi, P<0.05). Rates of transplantation were higher for RCM and CHD (P<0.01), whereas post-transplant survival remained unchanged.

conclusionsThe new allocation system has had a positive impact on time to transplantation of patients with RCM, HCM, and CHD without negatively influencing survival.

Indexed as

Heart TransplantationTissue and Organ ProcurementAdultCardiomyopathy, HypertrophicCardiomyopathy, RestrictiveFemaleHeart Defects, CongenitalHumansMaleMiddle AgedPolicyRegistriesUnited States

Identifiers

PMID33651802
PMCPMC7924739
OpenAlexW3134920837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.